Details

Autor(en) / Beteiligte

• Harrison, Paul
• Didembourg, Marie
• Wood, Alexander
• Devi, Amarpreet
• Dinsdale, Robert
• Hazeldine, Jon
• Alsousou, Joseph
• Keene, David J
• Hulley, Philippa
• Wagland, Susan
• Parsons, Scott
• Thompson, Jacqueline
• Byrne, Christopher
• Schlüssel, Michael Maia
• O'Connor, Heather
• Dutton, Susan J
• Lamb, Sarah E
• Willett, Keith

Titel

Characteristics of L-PRP preparations for treating Achilles tendon rupture within the PATH-2 study

Ist Teil von

• Platelets (Edinburgh), 2021-02, Vol.32 (2), p.273-279

Ort / Verlag

England: Taylor & Francis

Erscheinungsjahr

2021

Beschreibungen/Notizen

• Platelet-rich plasma (PRP) is an autologous preparation that has been claimed to improve healing and mechanobiological properties of tendons both in vitro and in vivo. In this sub-study from the PATH-2 (PRP in Achilles Tendon Healing-2) trial, we report the cellular and growth factor content and quality of the Leukocyte-rich PRP (L-PRP) (N = 103) prepared using a standardized commercial preparation method across 19 different UK centers. Baseline whole blood cell counts (red cells, leukocyte and platelets) demonstrated that the two groups were well-matched. L-PRP analysis gave a mean platelet count of 852.6 x 10 9 /L (SD 438.96), a mean leukocyte cell count of 15.13 x 10 9 /L (SD 10.28) and a mean red blood cell count of 0.91 x 10 12 /L (SD 1.49). The activation status of the L-PRP gave either low or high expression levels of the degranulation marker CD62p before and after ex-vivo platelet activation respectively. TGF-β, VEGF, PDGF, IGF and FGFb mean concentrations were 131.92 ng/ml, 0.98 ng/ml, 55.34 ng/ml, 78.2 ng/ml and 111.0 pg/ml respectively with expected correlations with both platelet and leukocyte counts. While PATH-2 results demonstrated that there was no evidence L-PRP is effective for improving clinical outcomes at 24 weeks after Achilles tendon rupture, our findings support that the majority of L-PRP properties were within the method specification and performance.